Market Update (NYSE:BAX): PharmaEngine and Merrimack Amend MM-398 License Agreement
September 26, 2014 at 04:56 AM EDT
[Business Wire] – TAIPEI, Taiwan–(BUSINESSWIRE)– PharmaEngine, Inc. (TWO:4162.TWO – News), announced today that the company has signed an Amendment to its License Agreement of MM-398 (aka PEP02, nanoliposomal irinotecan injection, nal-IRI) with Merrimack . . . → Read More: Market Update (NYSE:BAX): PharmaEngine and Merrimack Amend MM-398 License Agreement Similar Articles: Company Update (NYSE:BAX): Baxter and Merrimack Pharmaceuticals Enter into Exclusive Ex-U.S. Licensing Agreement to Develop and Commercialize Novel Cancer Compound MM-398 Market Update: Baxter International Inc (NYSE:BAX) – Baxter Announces Hemodialysis Dialyzer Expansion in Opelika, Alabama Stock Update: Baxter International Inc (NYSE:BAX) – Baxter to Present at Morgan Stanley Global Healthcare Conference